MedTrace Logo

Adipose Stem Cells for Traumatic Spinal Cord Injury

NCT03308565 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-08-30

No results posted yet for this study

Summary

The purpose of this study is to determine if mesenchymal stem cells (MSC) derived from the fat tissue can be safely administered into the cerebrospinal fluid (CSF) of patients with spinal cord injury. Adipose-derived mesenchymal stem cells (AD-MSCs) have been used in previous research studies at the Mayo Clinic. All subjects enrolled in this study will receive AD-MSC treatment, which is still experimental and is not approved by the U.S. Food and Drug Administration (FDA) for large scale use. However, the FDA has allowed the use of this agent in this research study.

Conditions

  • Spinal Cord Injuries
  • Paralysis

Interventions

BIOLOGICAL

Autologous, Adipose derived Mesenchymal Stem Cells

The mesenchymal stem cells will be collected and expanded from the subjects adipose tissue.

Sponsors & Collaborators

  • Mohamad Bydon

    lead OTHER

Principal Investigators

  • Mohamad Bydon, MD · Mayo Clinic, Rochester, MN

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-05
Primary Completion
2019-10-22
Completion
2021-10-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03308565 on ClinicalTrials.gov